secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055644
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca Q1 net loss $35.0M ($0.23/shr); cash $297.7M; naporafenib data shows 13-14 mo median OS
--------------------------------------------------------------------------------

- Net loss $35.0M vs $33.2M YoY; EPS $(0.23) vs $(0.22).
- Cash, equivalents & marketable securities $297.7M as of March 31, 2024.
- Pooled analysis of naporafenib + trametinib shows median OS 13.0-14.1 months in NRASm melanoma.
- Closed oversubscribed $45M private placement in April 2024, extending cash runway into H2 2026.
- Upcoming milestones: Phase 3 SEACRAFT-2 initiation Q2 2024; multiple data readouts in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017024055644/0000950170-24-055644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017024055644/eras-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer